ArticleJournal for immunotherapy of cancer2015
T cell-NF-κB activation is required for tumor control in vivo.
Article in Journal for immunotherapy of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 70 citations in OpenAlex.
- Recent progress in cGAS-STING agonist design and mechanisms of cancer immune modulation.RSC chemical biology · 2026Review
- Noninvasive in vivo imaging of NF-κB activation predicts immunotherapy response in solid tumors.Npj imaging · 2026Article
- SARDH in the 1-C metabolism sculpts the T-cell fate and serves as a potential cancer therapeutic target.Cellular & molecular immunology · 2025Article
- Construction of mitochondrial signature (MS) for the prognosis of ovarian cancer.Discover oncology · 2025Article
- Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma.Cancer immunology, immunotherapy : CII · 2025Article
- The NF-κB signaling network in the life of T cells.Frontiers in immunology · 2025Review
- Peroxisome Proliferator-Activated Receptor δ Suppresses the Cytotoxicity of CD8+ T Cells by Inhibiting RelA DNA-Binding Activity.Cancer research communications · 2024Article
- NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer.The Journal of experimental medicine · 2024Article
- The NF-κB RelA transcription factor is not required for CD8+ T-cell function in acute viral infection and cancer.Frontiers in immunology · 2024Article
- Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.Cancer immunology research · 2023Article
- Article
- Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets.Journal for immunotherapy of cancer · 2023Review
- Targeting inflammatory macrophages rebuilds therapeutic efficacy of DOT1L inhibition in hepatocellular carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Uncovering the mode of action of engineered T cells in patient cancer organoids.Nature biotechnology · 2023Article
- Single-cell analysis reveals differences among iNKT cells colonizing peripheral organs and identifies Klf2 as a key gene for iNKT emigration.Cell discovery · 2022Article
- TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- NF-κB in Cancer Immunity: Friend or Foe?Cells · 2021Review
- Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?Cancers · 2020Review
- p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy.Journal for immunotherapy of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundT cells have the capacity to eliminate tumors but the signaling pathways by which they do so are incompletely understood. T cell priming requires activation of the transcription factors AP-1, NFAT and NF-κB downstream of the TCR, but whether activation of T cell-NF-κB in vivo is required for tumor control has not been addressed. In humans and mice with progressively growing tumors, the activity of T cell-intrinsic NF-κB is often reduced. However, it is not clear if this is causal for an inability to reject transformed cells, or if it is a consequence of tumor growth. T cell-NF-κB is important for T cell survival and effector differentiation and plays an important role in enabling T cells to reject cardiac and islet allografts, suggesting the possibility that it may also be required for tumor elimination. In this study, we tested whether normal T cell-NF-κB activation is necessary for the rejection of tumors whose growth is normally controlled by the immune system.
methodsMice with genetically impaired T cell-NF-κB activity were subcutaneously injected with MC57-SIY tumor cells. Tumor growth was measured over time, and the anti-tumor immune response was evaluated using flow cytometry and cytokine detection assays.
resultsMice with impaired T cell-NF-κB activity were unable to reject tumors that were otherwise eliminated by wildtype mice, despite equal accumulation of tumor-reactive T cells. In addition, specific impairment of NF-κB signaling downstream of the TCR was sufficient to prevent tumor rejection. Tumor antigen-specific T cell-IFN-γ and TNF-α production, as well as cytotoxic ability, were all reduced in mice with impaired T cell-NF-κB, suggesting an important role for this transcription factor in the effector differentiation of tumor-specific effector T cells.
conclusionsOur results have identified the NF-κB pathway as an important signaling axis in T cells, required for the elimination of growing tumors in vivo. Maintaining or enhancing T cell-NF-κB activity may be a promising avenue for anti-tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.